Effect of MAO-B Inhibitors on Neurometabolic Profile of Patients Affected by Parkinson Disease: A Proton Magnetic Resonance Spectroscopy Study.
MAO-B inhibitors
N-acetylaspartate
Parkinson’s disease
cerebral cortex
choline
disease progression
neurometabolites
proton magnetic resonance spectroscopy
rasagiline
selegiline
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
30 Mar 2022
30 Mar 2022
Historique:
received:
09
02
2022
revised:
18
03
2022
accepted:
27
03
2022
entrez:
12
4
2022
pubmed:
13
4
2022
medline:
13
4
2022
Statut:
epublish
Résumé
Parkinson's Disease (PD) is the most common neurodegenerative movement disorder whose treatment is symptomatic. No suitable methods for assessing the effects of dopaminergic drugs on disease progression in clinical trials have yet been provided. The aim of this longitudinal study is to evaluate the influence of rasagiline and selegiline on neurometabolic profile in de novo PD patients by using Proton Magnetic Resonance Spectroscopy (
Identifiants
pubmed: 35407539
pii: jcm11071931
doi: 10.3390/jcm11071931
pmc: PMC8999805
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Italian Health Minister
ID : GR-2013-02359069
Références
Mov Disord. 2007 Nov 15;22(15):2170-5
pubmed: 17722082
Trends Neurosci. 2000 Oct;23(10 Suppl):S8-19
pubmed: 11052215
Mov Disord. 2003 Jul;18(7):738-50
pubmed: 12815652
Arch Neurol. 2001 Jan;58(1):65-70
pubmed: 11176938
Biomed Res Int. 2014;2014:519816
pubmed: 25302300
Front Neurol. 2019 Jul 17;10:777
pubmed: 31379726
Neural Regen Res. 2012 Mar 15;7(8):611-9
pubmed: 25745453
Eur J Radiol. 1999 May;30(2):125-31
pubmed: 10401593
Clin Ther. 2007 Sep;29(9):1825-49
pubmed: 18035186
J Neural Transm (Vienna). 2009 Nov;116(11):1371-81
pubmed: 19763773
Radiology. 2016 Feb;278(2):505-13
pubmed: 26237591
Curr Drug Targets. 2006 Nov;7(11):1513-29
pubmed: 17100591
Mov Disord. 2015 Sep;30(10):1400-4
pubmed: 26228901
J Neural Transm (Vienna). 2018 Nov;125(11):1735-1749
pubmed: 29417334
Magn Reson Med. 2006 Feb;55(2):296-301
pubmed: 16408282
Front Neurol. 2018 Sep 26;9:806
pubmed: 30319535
Mov Disord. 2018 Nov;33(11):1688-1699
pubmed: 30280416
Brain Behav. 2017 Aug 13;7(9):e00792
pubmed: 28948086
Neurosci Lett. 2015 Jul 10;599:55-60
pubmed: 26007705
NMR Biomed. 2008 May;21(4):381-7
pubmed: 17907264
AJR Am J Roentgenol. 2016 Feb;206(2):385-9
pubmed: 26797368
J Neuroimaging. 2019 Nov;29(6):707-711
pubmed: 31463990
Neurosci Lett. 2004 Jan 16;354(3):177-80
pubmed: 14700725
Mov Disord. 1997 May;12(3):297-301
pubmed: 9159722
Brain Imaging Behav. 2014 Mar;8(1):97-101
pubmed: 23955491
J Neurosci Res. 2002 Feb 1;67(3):285-9
pubmed: 11813232
Metab Brain Dis. 1999 Mar;14(1):45-55
pubmed: 10348313
J Neurol Neurosurg Psychiatry. 2013 Jun;84(6):644-9
pubmed: 23334525
Neurol Sci. 2001 Feb;22(1):69-70
pubmed: 11487206
J Neuroimaging. 2014 Jan-Feb;24(1):39-44
pubmed: 23228009